{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:25:06Z","timestamp":1787775906267,"version":"build-2784847793"},"reference-count":6,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 1","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aim:<\/jats:title>\n                    <jats:p>Heart failure is a common condition that affects millions of people worldwide. The aim of this study was to evaluate the 6-month effect of sacubitril-valsartan (SV) compared to angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) on left ventricular ejection fraction (LVEF) in heart failure patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This is a clinical trial involving heart failure patients (n = 225) referred to Farshchian Heart Hospital in Hamadan-Iran from April to September 2023. The patients were randomly assigned to three groups receiving SV (n = 75), ACEI (n = 75), and ARB (n = 75). In all three treatment groups, LVEF was checked and compared by echocardiography before the treatment and 6 months after the treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The mean scores of an increase in EF compared to before treatment in the SV, ACEI, and ARB groups were 1.73 \u00b1 2.78%, 0.69 \u00b1 1.93%, and 0.14 \u00b1 1.42%, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001) groups (29.3 vs. 6.7 and 12.7%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001). In addition, no significant difference was observed between the three groups in terms of mortality. The number of hospitalizations and the duration of hospitalization were lower in the sacubitril-valsartan group than in the ACEI and ARB groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In this study, SV was shown to be superior to ACEI and ARB in improving LVEF in heart failure patients at 6 months follow-up. These findings highlight the potential benefits of SV in the management of heart failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jpbs.jpbs_133_25","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T02:32:08Z","timestamp":1746066728000},"page":"S795-S797","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the 6-Month Effect of Sacubitril-Valsartan Compared to ACEI and ARB on LVEF in Heart Failure Patients: A Double-Blind Randomized Clinical Trial"],"prefix":"10.4103","volume":"17","author":[{"given":"Farnosh","family":"Masmoo","sequence":"first","affiliation":[{"name":"Department of Cardiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farnaz","family":"Fariba","sequence":"additional","affiliation":[{"name":"Department of Cardiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakissa","family":"Khansari","sequence":"additional","affiliation":[{"name":"Department of Cardiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Farhadian","sequence":"additional","affiliation":[{"name":"Department of Cardiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"R1-20250513","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","article-title":"Combined angiotensin receptor antagonism and neprilysin inhibition","volume":"133","author":"Hubers","year":"2016","journal-title":"Circulation"},{"key":"R2-20250513","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/heartjnl-2014-306775","article-title":"The neprilysin pathway in heart failure: A review and guide on the use of sacubitril\/valsartan","volume":"102","author":"Jhund","year":"2016","journal-title":"Heart"},{"key":"R3-20250513","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijcard.2022.01.004","article-title":"Benefit from sacubitril\/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study","volume":"350","author":"Carluccio","year":"2022","journal-title":"Int J Cardiol"},{"key":"R4-20250513","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/ehf2.13779","article-title":"Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril\/valsartan","volume":"9","author":"Dini","year":"2022","journal-title":"ESC Heart Fail"},{"key":"R5-20250513","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jchf.2019.08.003","article-title":"Comparative effectiveness of sacubitril-valsartan versus ACE\/ARB therapy in heart failure with reduced ejection fraction","volume":"8","author":"Tan","year":"2020","journal-title":"JACC Heart Fail"},{"key":"R6-20250513","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1002\/ehf2.13677","article-title":"The benefits of sacubitril\u2013valsartan in patients with acute myocardial infarction: A systematic review and meta-analysis","volume":"8","author":"Xiong","year":"2021","journal-title":"ESC Heart Fail"}],"container-title":["Journal of Pharmacy and Bioallied Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_133_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:45:13Z","timestamp":1787773513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_133_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":6,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jpbs.jpbs_133_25","relation":{},"ISSN":["0976-4879","0975-7406"],"issn-type":[{"value":"0976-4879","type":"print"},{"value":"0975-7406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"2025-01-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}